← Axsome Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $50.0m |
$270.6m
+440.80%
|
$385.7m
+42.53%
|
$638.5m
+65.55%
|
$708.2m
+10.92%
|
|
| Cost of Goods and Services Sold | — | — | — | — | $70.2m |
$58.1m
-17.34%
|
$5.2m
-91.04%
|
$26.1m
+401.25%
|
$33.3m
+27.77%
|
$47.5m
+42.56%
|
$52.4m
+10.40%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | $70.2m |
$58.1m
-17.34%
|
$5.2m
-91.05%
|
$26.1m
+401.48%
|
$33.3m
+27.77%
|
$47.5m
+42.56%
|
$52.4m
+10.40%
|
|
| Cost of revenue (excluding amortization and depreciation) | — | — | — | — | $70.2m |
$58.1m
-17.34%
|
$5.2m
-91.05%
|
$26.1m
+401.48%
|
$33.3m
+27.77%
|
$47.5m
+42.56%
|
$52.4m
+10.40%
|
|
| Gross Profit (Calculated) | — | — | — | — | — | — | $44.8m |
$244.5m
+445.39%
|
$352.4m
+44.11%
|
$591.0m
+67.72%
|
— | |
| Research and Development Expense | $21.2m | $20.0m | $23.5m | $53.6m | $70.2m | $58.1m | $57.9m | $97.9m | $187.1m | $183.3m | $191.2m | |
| Selling, General and Administrative Expense | — | — | — | — | $28.9m | $66.6m | $159.3m | $323.1m | $411.4m | $570.6m | $634.8m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | $4.1m | $6.4m | $6.4m | $6.4m | — | |
| Operating Lease, Expense | — | — | — | — | — | $1.2m | $1.3m | $2.2m | — | — | — | |
| Operating Expenses | $27.5m | $27.2m | $32.8m | $67.2m | $99.1m | $124.7m | $229.8m | $502.4m | $666.3m | $805.3m | $832.4m | |
| Loss from operations | ($27.5m) |
($27.2m)
+1.38%
|
($32.8m)
-20.92%
|
($67.2m)
-104.72%
|
($99.1m)
-47.43%
|
($124.7m)
-25.79%
|
($179.8m)
-44.18%
|
($231.8m)
-28.94%
|
($280.6m)
-21.02%
|
($166.8m)
+40.56%
|
— | |
| Operating Income (Loss) | ($27.5m) |
($27.2m)
+1.38%
|
($32.8m)
-20.92%
|
($67.2m)
-104.72%
|
($99.1m)
-47.43%
|
($124.7m)
-25.79%
|
($179.8m)
-44.18%
|
($231.8m)
-28.94%
|
($280.6m)
-21.02%
|
($166.8m)
+40.56%
|
($176.5m)
-5.86%
|
|
| Interest Expense | — | — | — | — | — | — | — | — | ($21.6m) | ($15.9m) | $5.3m | |
| Interest expense, net | ($132k) | ($1.3m) | ($1.1m) | ($1.2m) | ($2.6m) | ($5.7m) | ($7.3m) | ($6.5m) | ($6.6m) | ($6.6m) | $5.3m | |
| Interest Income, Operating | — | — | — | — | — | — | — | — | $15.0m | $9.4m | — | |
| Investment Income, Net | ($132k) | ($1.3m) | ($1.1m) | ($1.2m) | ($2.6m) | ($5.7m) | ($7.3m) | ($6.5m) | ($6.6m) | ($6.6m) | — | |
| Loss before income taxes | — | — | — | — | — | ($130.4m) | ($187.1m) | ($238.3m) | ($287.1m) | ($183.7m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $130.4m | $187.1m | ($238.3m) | ($287.1m) | ($183.7m) | ($188.8m) | |
| Income Tax Expense (Benefit) | — | — | $0 | $0 | $0 | $0 | $0 | $960k | $85k | ($530k) | ($530k) | |
| Net loss | ($27.2m) | ($28.9m) | ($31.0m) | ($68.3m) | ($102.9m) | ($130.4m) | ($187.1m) | ($239.2m) | ($287.2m) | ($183.2m) | — | |
| Net Income (Loss) Attributable to Parent | ($27.2m) |
($28.9m)
-6.40%
|
($31.0m)
-6.99%
|
($68.3m)
-120.71%
|
($102.9m)
-50.56%
|
($130.4m)
-26.73%
|
($187.1m)
-43.50%
|
($239.2m)
-27.84%
|
($287.2m)
-20.05%
|
($183.2m)
+36.22%
|
($188.3m)
-2.80%
|
|
| Earnings Per Share, Basic | ($1.42) | ($1.27) | ($1.15) | ($2.01) | ($2.77) | ($3.47) | ($4.60) | ($5.27) | ($5.99) | ($3.68) | ($3.72) | |
| Earnings Per Share, Diluted | ($1.42) | ($1.27) | ($1.15) | ($2.01) | ($2.77) | ($3.47) | ($4.60) | ($5.27) | ($5.99) | ($3.68) | ($3.72) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 37.2m | 37.6m | 40.7m | 45.4m | 47.9m | 49.7m | 50.3m | |
| Weighted average common shares outstanding, basic | — | — | — | — | 37.2m | 37.6m | 40.7m | 45.4m | 47.9m | 49.7m | — | |
| Weighted average common shares outstanding, diluted | — | — | — | — | 37.2m | 37.6m | 40.7m | 45.4m | 47.9m | 49.7m | — | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 37.2m | 37.6m | 40.7m | 45.4m | 47.9m | 49.7m | 50.3m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $27.5m | $27.2m | $32.8m | $67.2m | $99.1m | $124.7m | $229.8m | $502.4m | $666.3m | $805.3m | — | |
| Loss (Gain) in fair value of contingent consideration | — | — | — | — | — | — | $3.3m | $48.9m | $28.1m | ($2.5m) | — | |
| Intangible asset amortization | — | — | — | — | — | — | $4.1m | $6.4m | $6.4m | $6.4m | — | |
| Loss on debt extinguishment | — | — | — | — | ($1.2m) | — | — | — | — | ($10.4m) | — | |
| Tax credit | $474k | $207k | $217k | $139k | $54k | — | — | — | — | — | — |